These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 6673058)
1. Prednisolone pharmacokinetics and protein-binding in patients with portosystemic shunt. Bergrem H; Ritland S; Opedal I; Bergan A Scand J Gastroenterol; 1983 Mar; 18(2):273-6. PubMed ID: 6673058 [TBL] [Abstract][Full Text] [Related]
2. Bioavailability of prednisolone in patients with intestinal malabsorption: the importance of measuring serum protein-binding. Bergrem H; Opedal I Scand J Gastroenterol; 1983 May; 18(4):545-9. PubMed ID: 6669930 [TBL] [Abstract][Full Text] [Related]
3. Corticosteroids in liver disease: studies on the biological conversion of prednisone to prednisolone and plasma protein binding. Powell LW; Axelsen E Gut; 1972 Sep; 13(9):690-6. PubMed ID: 4639403 [TBL] [Abstract][Full Text] [Related]
4. Prednisone for chronic active hepatitis: pharmacokinetics and serum binding in patients with chronic active hepatitis and steroid major side effects. Uribe M; Go VL; Kluge D J Clin Gastroenterol; 1984 Aug; 6(4):331-5. PubMed ID: 6481116 [TBL] [Abstract][Full Text] [Related]
5. The influence of uremia on pharmacokinetics and protein binding of prednisolone. Bergrem H Acta Med Scand; 1983; 213(5):333-7. PubMed ID: 6880855 [TBL] [Abstract][Full Text] [Related]
6. Comparative serum prednisone and prednisolone concentrations following administration to patients with chronic active liver disease. Uribe M; Summerskill WH; Go VL Clin Pharmacokinet; 1982; 7(5):452-9. PubMed ID: 7140120 [TBL] [Abstract][Full Text] [Related]
8. Decreased first-pass metabolism of labetalol in chronic liver disease. Homeida M; Jackson L; Roberts CJ Br Med J; 1978 Oct; 2(6144):1048-50. PubMed ID: 709214 [TBL] [Abstract][Full Text] [Related]
9. Prednisone for chronic active liver disease: pharmacokinetics, including conversion to prednisolone. Schalm SW; Summerskill WH; Go VL Gastroenterology; 1977 May; 72(5 Pt 1):910-3. PubMed ID: 849821 [TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics of prednisolone in children with acute lymphoblastic leukemia. Petersen KB; Jusko WJ; Rasmussen M; Schmiegelow K Cancer Chemother Pharmacol; 2003 Jun; 51(6):465-73. PubMed ID: 12698270 [TBL] [Abstract][Full Text] [Related]
11. The absence of effect of azathioprine on prednisolone pharmacokinetics following maintenance prednisone doses in kidney transplant patients. Gambertoglio JG; Holford HG; Lizak PS; Birnbaum JL; Salvatierra O; Amend WJ Am J Kidney Dis; 1984 May; 3(6):425-9. PubMed ID: 6372445 [TBL] [Abstract][Full Text] [Related]
12. Altered prednisolone pharmacokinetics in patients treated with rifampicin. Bergrem H; Refvem OK Acta Med Scand; 1983; 213(5):339-43. PubMed ID: 6880856 [TBL] [Abstract][Full Text] [Related]
13. Corticosteroid pharmacokinetics in liver disease. Uribe M; Go VL Clin Pharmacokinet; 1979; 4(3):233-40. PubMed ID: 383357 [TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and protein binding of prednisolone after oral and intravenous administration. Bergrem H; Grøttum P; Rugstad HE Eur J Clin Pharmacol; 1983; 24(3):415-9. PubMed ID: 6861855 [TBL] [Abstract][Full Text] [Related]